FDA Lays Out Rules For Early Study Of Higher-Risk Devices
The U.S. Food and Drug Administration on Tuesday laid out new expectations for early clinical studies of higher-risk medical devices, describing a litany of conditions manufacturers must meet before such analyses...To view the full article, register now.
Already a subscriber? Click here to view full article